Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 21, Art. 69 (pp. 854-869)    |    2020       

»

Perftooran. Unused potential of medicine against covid-19.

Institute for Theoretical and Experimental Biophysics, Russian Academy of Sciences
IPI ?Institute of Engineering Physics?, Serpukhov, Moscow Region. Russia

Brief summary

This brief review compares the known clinical symptoms and identified pathogenetic mechanisms of COVID-19 with the unique properties of the Russian gas-carrying blood substitute Perftoran, which is a nanoemulsion of completely fluorinated organic compounds. A generalized analysis of the results of more than 20 years of clinical Perftoran use allows us to propose it as a target agent capable of significantly reducing the harmful effects of key factors responsible for the damage to the human body and deaths in coronavirus infection. Attention is focused on the main features of Perftoran action: the ability to weaken the effect of hemic, circulatory, thromboembolic and respiratory hypoxia, to provide partial replacement of the oxygen-carrying function of damaged erythrocytes and hemoglobin, to exhibit a cytoprotective effect at the level of the lung alveoli, erythrocytes, vascular endothelium and other tissues, to reduce the primary damage and secondary inflammatory alteration. Clinical experience in relief of acute respiratory distress syndrome (ARDS), prevention of disseminated intravascular coagulation, and treatment of thromoembolism with Perftoran is mentioned. Many therapeutic effects have been demonstrated previously with intravenous, as well as with local and aerosol administration of the drug. In fact, the article substantiates the need to restore the industrial manufacturing of Perftoran, which was stopped due to financial reasons.


Key words

COVID-19, Perftoran, antihypoxic, anti-inflammatory, anticoagulant properties, ARDS treatment, thromboembolism, cytoprotection, improving blood flow.

Reference list

1. Sonya Trayss. Vedomosti [http://plus-one.vedomosti.ru/blog/lichnoe]


2. Dmitrii Zdornikov VOZ nazvala deksametazon naychnim prorivom iz-za nekompetentnosti Ediger[https://www.osnmedia.ru/obshhestvo/voz-nazvala-opasnyj-deksametazon...]


3. Guo Y.R., Cao Q.D., Hong Z.S., Tan Y.Y., Chen S.D., Jin H.J., Tan K.S., Wang D.Y., Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0.


4. See A., Toh S.T. Respiratory Sampling for SARS-CoV-2 - An Overview. Head Neck. 2020 May 1. doi: 10.1002/hed.26232;


5. Vremennie metodicheskie rekomendacii: Profilaktika i lechenie novoi koronavirysnoi infekcii (COVID-19)» Minzdrav RF. Versiya 6 (28.04.2020).


6. Şimşek Yavuz S., Ünal S. Antiviral treatment of COVID-19 Turk J Med Sci. 2020 Apr 21;50(SI-1):611-619. doi: 10.3906/sag-2004-145;


7. Ozma M.A., Maroufi P., Khodadadi E., Köse Ş., Esposito I., Ganbarov K., Dao S., Esposito S., Dal T., Zeinalzadeh E., Kafil H.S. Clinical manifestation, diagnosis, prevention and control of SARS-CoV-2 (COVID-19) during the outbreak period. Infez Med. 2020 Ahead of print Jun 1;28(2):153-165.


8. Salzberger B, et al. Epidemiology of SARS-CoV-2 infection and COVID-19. Review article. Internist (Berl). 2020 Jun 16. doi: 10.1007/s00108-020-00834-9. [Epub ahead of print]


9. A.J. Rodriguez-Morales, J.A. Cardona-Ospina, E. Gutiérrez-Ocampo et al., Clinical, Laboratory and Imaging Features of COVID-19: A Systematic Review and Meta-Analysis/Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19). Electronic address:[https://www.lancovid.org/ Meta-Analysis. Travel Med Infect Dis. Mar-Apr 2020; 34:101623. doi: 10.1016/j.tmaid.2020.101623. Epub 2020 Mar 13.]


10. BCJ vakcinaciya: [https://www.youtube.com/watch?list=PLp...]


11. Ledford H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature. 2020 Jun 16. doi: 10.1038/d41586-020-01824-5. Online ahead of print.PMID: 32546811,


12. I. Hamming, W. Timens, M.L.C. Bulthuis, A.T. Lely, G.J. Navis, H. van Goor Tissue Distribution of ACE2 Protein, the Functional Receptor for SARS Coronavirus. A First Step in Understanding SARS Pathogenesis // J Pathol. 2004; 203(2):631-7. doi: 10.1002/path.1570.


13. Nina Jelydkov «Sibirskie ychenie podarili italyancam sposob lecheniya koronavirysa». Intervu s A.A. Gromovim. 26.04.2020 [https://m.sibkray.ru/news/1/934835/],


14. Levi M., Thachil J., Iba T., Levy J.H. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020 May 11. pii: S2352-3026(20)30145-9. doi: 10.1016/S2352-3026(20)30145-9. [Epub ahead of print];


15. Ren B,.Yan F., Deng Z., Zhang S., Xiao L., Wu M., Cai Extremely High Incidence of Lower Extremity Deep Venous Thrombosis in 48 Patients with Severe COVID-19 in Wuhan. L Circulation. 2020 May 15. doi: 10.1161/ Circulation AHA.120.047407. [Epub ahead of print].


16. Mucha S.R., Dugar S., McCrae K., Joseph D.E., Bartholomew J., Sacha G., Militello M. Coagulopathy in COVID-19. Cleve Clin J Med. 2020 May 14. doi: 10.3949/ccjm.87a.ccc024. [Epub ahead of print].


17. Profilaktika, diagnostika i lechenie novoi koronavirysnoi infekcii COVID-19. Vremennie metodicheskie rekomendacii Minzdrava Rossii v kratkoi variante versii 6 [https://static.rosminzdrav.ru/system./attachments/attaches/000/050/143/ original/COVID-19-V6.pdf?1588331460].


18. Perftoran (Material Vikipedii, predstavlen S.I. Vorobevim), sm. takje wiki2.org/ru/Perftoran


19. Golybev A.M. Perftoran - plazmozamenitel s fynkciei transporta kisloroda //Bul eksper. biol. i med. 1998. T. 125, 5. S.484-3492.


20. L.A. Bogdanova, E.I. Maevskii, R.Ya. Senina, S.U. Pyshkin, O.G.Aksenova, G.R.Ivanickii Kratkii obzor klinicheskogo primeneniya perftorana //Biomedicinskii jyrnal medline.ru 2001, T. 2, ST. 5, c. 30-36.


21. Maevsky E, Ivanitsky G, Bogdanova L, Axenova O, Karmen N, Zhiburt E, et al. Clinical results of Perftoran application: present and future. Artif Cells Blood Substit Immobil Biotechnol. 2005;33(1):37-46. doi: 10.1081/bio-200046654.PMID: 15768564.


22. J.G. Riess Perfluorocarbon-based Oxygen Delivery. Artif Cells Blood Substit Immobil Biotechnol. 2006;34(6):567-80. doi:10.1080/10731190600973824.


23. Perftororganicheskie soedinenii v eksperimentalnoi i klinicheskoi medicine. Bibliograficheskii ykazatel (1966-2001 gg.). Pod obshei red. akad. G.A. Sofronova. Sankt-Peterbyrg. 2002 g. 268 s.


24. «O prinyatii na snabjenie medicinskoi slyjbi Vooryjennih sil Rossiiskoi Federacii plazmozameshaushego sredstva s gazoperenosyashei fynkciei Perftoran v lekarstvennoi forme -emylsii dlya infyzii» Prikaz nachalnika Glavnogo voenno-medicinskogo ypravleniya MO RF 341 341 ot 26.06.1998 g.


25. Gervits L.L., Makarov K.N., Maevsky E.I., Ivanitsky G.R., Pushkin S.Ju., Maslennikov I.A. Perfluoronated Cycle-Containing Tertiary Amines used as A Basis for Gas-Conveying Emulsions and Device for Production Thereof// Patent No: US 6,878,826 B2, -: Date of Patent: Apr.12, 2005


26. Novikova M.D., Nesterova A.N., Shabalin D.A., Gervic L.L. Sposob polycheniya perftorirovannih ciklosoderjashih tretichnih aminov. Patent RF 2 686 491 Prioritet ot 17.10.2018, Opyblikovan 29.04.2019. Bul. 13]


27. Maevskii E.I., Ivanickii G.R., Makarov K.N., Kylakova G.N., Arhipov V.V., Moroz V.V., Starovoitova L.N., Senina R.Ya., Pyshkin S.U., Ivashina A.I. Emylsiya perftororganicheskih soedinenii dlya medicinskih celei, sposob ee prigotovleniya i sposobi lecheniya i profilaktiki zabolevanii s ee ispolzovaniem. Patent RF ? 2206319, Prioritet 20.07.2000. Pyblikaciya ot 20.06.2003 (zarybejnoe patentovanie: E.I..Maevsky, G.R.Ivanitsky, K.N.Makarov et al. /Emulsion of perfluororganic compounds for medical purposes, Method for producing said Emulsion and Methods for Curing and Preventing Diseases with the aid of Emulsion The European Patent 00970349.7-2112-RU0000309. Date of filing: 20.07.00. Notification of the data mentioned in Article 128(5) EPC pursuant to Rule 17(3) EPC from 26.02.03.; //E.I.Maevsky, G.R.Ivanitsky, K.N.Makarov et al / Emulsion of perfluororganic compounds for medical purposes, a process for preparation thereof and methods for treating and preventing Diseases with the use of thereof. United State Patent No. US 6,562,872,B1, May 13,2003).


28. OOO «Groteks» - proizvodstvennaya kompaniya firmi Solopharm [https://www.vidal.ru/drugs/perftoran_20674].


29. Moroz V.V., Maevskii E.I., Ivanickii G.R., Karmen N.B., Bogdanova L.A., Lejneva I.E., Hijnyak E.P., Hijnyak L.N., Petrova I.N., Orlov A.A., Syvorova N.V. Emylsiya perftororganicheskih soedinenii kak sredstvo dlya lecheniya naryshenii regionalnogo krovotoka// Obshaya reanimatologiya,- , 2007, - 3(1), C.:49-53


30. Ivanickii G.R. Biofizika na poroge novogo tisyacheletiya: perftoryglerodnie sredi i gazotransportnie krovezameniteli. Biofizika. 2001, t. 46, 1, s. 5 - 33.


31. Ivanickii G.R., Deev A.A., Maevskii E.I., Hijnyak E.P., Hijnyak L.N. Vozmojnosti termografii v sovremennoi medicine: issledovanie prostranstvennogo izmeneniya temperatyri koji cheloveka pri vvedenii perftorana. DAN, 2003, t. 393, 3, s. 419 - 423.


32. S.F. Bagnenko, V.V. Soroka, S.P. Nohrin, K.A. Andreichyk Primenenie perftorana v lechenii bolnih s kriticheskoi ishemiei nijnih konechnostei. // Biomedicinskii jyrnal www.medline.ru hiryrgiya, sentyabr 2005. T. 6, s.683-693


33. Nedospasov A.A., Beda N.V. Perftoran: revolucionnaya kombinaciya. Priroda, 2005, 8 (po Proektam RFFI: 02-04-49530 - Micellyarnoe okislitelnoe nitrozirovanie; 03-04-06492 - NO i «Perftoran»: revolucionnaya kombinaciya.) [http://vivovoco.astronet.ru /vv/journal/nature/08_05/perftoran.htm]


34. Rafikova O., Sokolova E., Rafikov R., Nudler E. Control of plasma NO bioactivity by perfluorocarbons: physiological mechanism s and clinical implications // Circulation. 2004. V.110. N.23 P.3573-3580.


35. Rafikova O.V. Regylyaciya yrovnya oksida azota v krovi pod deistviem albymina i emylsii perftoryglevodorodov. Avtoref. Kand. diss., kbn. spec. «fiziologiya». M. 2005. 24 s.


36. Moroz V. V., Molchanova L. V., Gerasimov L. V., Ostapchenko D. A., Ershova L. I., Lihoveckaya Z. M., Gorbynova N. A. Vliyanie perftorana na gemoreologiu i gemoliz y bolnih s tyajeloi travmoi i krovopoterei//Obshaya reanimatologiya. 2006.t.II, 1, s. 5-11.


37. D.U. Lazarenko, M.D. Hanevich, G.A. Sofronov, N.B. Andreeva, G.A. Poddybskii Vliyanie perftorana na mikrocirkylyaciu i reologicheskie svoistva krovi y bolnih s gastrodyodenalnimi krovotecheniyami//Biomedicinskii jyrnal medline.ru 2004. T. 5, ST. 17. c. 70-73.


38. Efendiev M.M. Profilaktika i lechenie tromboembolicheskih oslojnenii pri postgemorragicheskih anemiyah v ginekologii //Vestnik novih medicinskih tehnologii. 2007. 2. S. 76-79.


39. A.M. Golybev, A.N. Kyzovlev, D.V. Syndykov, M.A. Golybev Morfologicheskaya harakteristika legkih pri ingalyacii lipopolisaharida i perftorana//Obshaya reanimatologiya. 2015, T. 11, 1, s. 6-13. [https://doi.org/10.15360/1813-9779-2015-1-6-13]


40. Zaharov A.M., Maevskii E.I., Karmen N.B., Milutina N.P. Perftoran kak membranotropnii agent//Vestnik novih medicinskih tehnologii 2007 -4 - S.150-152.


41. Beloyarcev F.F., Kaidash A.N., Islamov B.I., Maevskii E.I., Kokoz D.M., Freidin A.A., Obrazcov V.V. Ocenka vozmojnostei ispolzovaniya ftoryglerodnoi kardioplegii dlya protivoishemicheskoi zashiti miokarda. // Vestnik AMN SSSR, 1986, Sh, s.37-43.


42. Afanasev D.V., Krichevskii A.L., Galeev I.K., Sivoronov K.N., Samoilova T.K., Rydaev V. I. Sposob lecheniya tyajeloi kompressionnoi travmi myagkih tkanei //Patent RF 2 289 395. Prioritet ot 05.11.2004. Opyblikovano: 20.12.2006 Bul. 35.


43. Shymakov V.I., Onishenko N.A., Saitgareev R.Sh. i dr. Primenenie perftoryglerodnoi emylsii pri transplantacii legkih (eksperim. issled.) // Biosovmestimost. - 1993. - T.1, 2. - S.57-65.


44. S.F. Bagnenko, Ya.G. Moisuk, O.N. Reznik, V.V. Shilov Perspektivi primeneniya perftorana pri izyatii pochek ot asistolicheskih donorov//Biomedicinskii jyrnal medline.ru 2004. T.5, ST.68, s. 212-213.


45. Obrazcov V.V., Shehtman D.G., Sklifas A.N., Makarov K.N., Analiz fiziko-himicheskih svoistv ftoryglerodnih indyktorov citohroma P-450 v membranah endoplazmaticheskogo retikylyma pecheni // Biohimiya. - 1988. - T.53, vip.4. - S.613-619.


46. Ushenko A.A., Yrlyapova N.G., Shac E.I., Savin L.A. Sredstvo dlya lecheniya troficheskih yazv i ojogov y bolnih leproi// Patent RF 2205643. Prioritet ot 13.05.2002. Opyblikovano: 10.06.2003. Bul. 16.


47. Lobzin U.V, Gysev D.A., Jelezkova E.V., Kovelenov A.U., Plyjnikov N.N. Immynologicheskie effekti perftorana// Eksper. klinich. farmakologiya. 1998. T.61., 5, s.34-36.


48. Kovelenov A.U., Mihalcov A.N., Malkov A.N. Perftoran kak sredstvo modylyacii fynkcionalnoi aktivnosti pechenochnih makrofagov// Bul. eksper. biol. i medicini. 2002. N 12. S.637-640 doi: 10.1023/a:022905027083.PMID: 12660835


49. Lobzin U.V, Kovelenov A.U. Perftoryglerodnie soedineniya kak novoe napravlenie patogeneticheskoi terapii tyajelih form virysnih gepatitov // Klinicheskaya medicina, 2003.-N 5.-S.47-51.


50. Plyjnikov N.N., Kovelenov A.U., Lobzin U.V., Sosukin A.E., Nakatis Ya.A., Bakylina L.S., Razymova D.V. Sposob lecheniya ostrih form virysnogo gepatita v i mikst-gepatitov (B + C, B + D, B + C + D)//Patent RF 2446798. Prioritet ot 25.03.2010. Opyblikovano: 10.04.2012 Bul. 10.


51. Vercellotti G.M., Hammerschmidt D.E., Craddock P.R., Jacob H.S., Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis//Blood. 1982, V.59, I.6, pp.1299-1304.


52. S.F. Flaim, Pharmacokinetics and Side Effects of Perfluorocarbon-Based Blood Substitutes//Artificial Cells, Blood Substitutes, and Biotechnology 1994, V.22, I.4, pp.1043-54. /doi: 10.3109/10731199409138801.


53. S.F. Flaim, D.R. Hazard, J. Hogan &R.M. Peters, Characterization and Mechanism of Side-Effects of Oxygent HT (Highly Concentrated Fluorocarbon Emulsion) in Swine//Artificial Cells, Blood Substitutes, and Biotechnology 1994, V.22, I.4, P.1511-1515./Published online: 11 Jul 2009.


54. E.I. Maevskii. Vozmojnie prichini ostroi reaktogennosti emylsii perftoryglerodov. Chast 1. Perftoran. // IZVESTIYa Instityta injenernoi fiziki. 2016. 1(39). s.79-87.


55. Chang H., Li M-H., Chen, C-W., Yan H-C., Huang K-L., Chu S-J. Intravascular FC-77 attenuates phorbol myristate acetate-induced acute lung injury in isolated rat lungs.// Critical Care Medicine. 2008, V.36, I.4, pp1222-1229.


56. A.A. Barsykov, M. A. Godkov, V. M. Zemskov, A. I. Vetoshkin, A. N. Diashev Rol praimirovannih neitrofilov v povrejdenii parenhimatoznih organov i razvitii vospalitelnoi patologii// Yspehi sovremennoi biologii, 2004, t. 124, 6, s. 542-554.


57. Shehtman D.G., Sklifas A.N., Safronova V.G., Gabdylhakova A.G., Kapcov V.V., Ponomarchyk V.V., N.I. Kykyshkin Fynkcionalnoe sostoyanie neitrofilov v prisytstvii emylsii PFOS// Sb. Perftororganicheskie soedineniya v biologii i medicine. Red. G.R. Ivanickii, V.V. Moroz, S.U. Pyshkin, R.Ya. Senina. Pyshino. NPO «Perftoran». 1999. S.222-227.


58. Dalgatov G.D., Medjidov R.T. Sredstvo dlya lecheniya i profilaktiki patologicheskogo razrastaniya soedinitelnoi tkani v parenhimatoznih organah" Patent RF 2146133. Prioritet ot 2.07.96 Opyblikovano: 10.03.2000 Bul. 7.


59. Kligynenko E.N., Sorokina E.U., Rojko V.I., Nikitchenko N.N. Mestnoe primenenie perftorana v kompleksnom lechenii dlitelno zajivaushih ran. Sb. Perftororganicheskie soedineniya v biologii i medicine. Red. G.R. Ivanickii, V.V. Moroz, S.U. Pyshkin, R.Ya. Senina. Pyshino. NPO «Perftoran». 1999. S.146-150.


60. Moroz V.V., Ostapchenko D.A., Vlasenko A.V. Sposob lecheniya ostrogo respiratornogo distress-sindroma //Patent RF 226 434 Prioritet ot 30.09.2003. Opyblikovano: 10.12.2005 Bul. 34.


61. Moroz V.V. «Ostrii rspiratornii distress-sindrom i CJVID-19» Doklad na onlain-zasedanii Buro Sekcii mediko-ibologicheski nayk OMN RA 05.06.2020. Mejdynarodnii myltimediinii press-centr MIA "Rossiya segodnya?[http://www.sib-science.info/ru/ras/lechenie-covid-19-02062020] (Nadejda Volchkova «Na linii zashiti. Ychenie i mediki sovmestno protivostoyat koronavirysy»// Poisk. 12.05.2020, 24. S. 3).


62. Bruce D. Spiess. Perfluorocarbon Gas Transport: An Overview of Medical History with Yet Unrealized Potentials. Short title: Perfluorocarbon Overview. // Military supplement to shock journalIntroduction to Western Medicine. Shock. 2017.d of Print. 2018.


63. [https://pubchem.ncbi.nlm.nih.gov/compound/Perflubron]


64. F. Khan, K. Singh, M.T. Friedman Artificial Blood: The History and Current Perspectives of Blood Substitutes// DISCOVERIES. 2020, Jan-Mar, 8(1): 1-15. e104 DOI: 10.15190/d.2020.1